Nektar Therapeutics logo

Nektar Therapeutics

NAS:NKTR (USA)  
1
$ 0.60 +0.0005 (+0.08%) 04:00 PM EST
P/E:
At Loss
P/B:
0.47
Market Cap:
$ 114.01M
Enterprise V:
$ -214.75M
Volume:
4.55M
Avg Vol (2M):
3.13M
Also Trade In:
Volume:
4.55M
Market Cap $:
114.01M
PE Ratio:
At Loss
Avg Vol (2M):
3.13M
Enterprise Value $:
-214.75M
PB Ratio:
0.47

Business Description

Description
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
Name Current Vs Industry Vs History
Cash-To-Debt 3.56
Equity-to-Asset 0.43
Debt-to-Equity 0.53
Debt-to-EBITDA -0.34
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -9.28
Distress
Grey
Safe
Beneish M-Score -3.23
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 33.46
9-Day RSI 33.37
14-Day RSI 34.63
6-1 Month Momentum % -71.87
12-1 Month Momentum % -77.51

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 8.2
Quick Ratio 7.86
Cash Ratio 7.63
Days Inventory 283.64
Days Sales Outstanding 49.91
Days Payable 146.65

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.2

Financials (Next Earnings Date:2023-08-04 Est.)

NKTR's 30-Y Financials
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:NKTR

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
To

Annualized Return %

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Nektar Therapeutics Executives

Details

Valuation chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 88.827
EPS (TTM) ($) -2.21
Beta 0.68
Volatility % 82.66
14-Day RSI 34.63
14-Day ATR ($) 0.047633
20-Day SMA ($) 0.66218
12-1 Month Momentum % -77.51
52-Week Range ($) 0.5801 - 5.18
Shares Outstanding (Mil) 189.24

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Nektar Therapeutics Filings

Document Form Filing Date
No Filing Data

Nektar Therapeutics Stock Events

Event Date Price($)
No Event Data

Nektar Therapeutics Frequently Asked Questions

What is Nektar Therapeutics(NKTR)'s stock price today?
The current price of NKTR is $0.60. The 52 week high of NKTR is $5.18 and 52 week low is $0.58.
When is next earnings date of Nektar Therapeutics(NKTR)?
The next earnings date of Nektar Therapeutics(NKTR) is 2023-08-04 Est..
Does Nektar Therapeutics(NKTR) pay dividends? If so, how much?
Nektar Therapeutics(NKTR) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1